Skip to content

ImmunityBio, Inc. IBRX Professional Service Fees Payable

Professional Service Fees Payable at other companies

Immunovant, Inc. logo
Immunovant, Inc.IMVT
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.71B+208%
Enterprise value$7.95B+187%
P/S54.7×-25.4×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedProfessionalFeesCurrent.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s professional service fees payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ImmunityBio, Inc.'s professional service fees payable?
ImmunityBio, Inc. (IBRX) reported professional service fees payable of $12.25M in Q1 2026.
How has ImmunityBio, Inc.'s professional service fees payable changed year-over-year?
ImmunityBio, Inc.'s professional service fees payable increased by 50.9% year-over-year, from $8.12M to $12.25M.
What is the long-term trend for ImmunityBio, Inc.'s professional service fees payable?
Over 5 years (2020 to 2025), ImmunityBio, Inc.'s professional service fees payable has grown at a -0.4% compound annual growth rate (CAGR), from $7.67M to $7.51M.